Taken together, UF146 treatment leads to MXD4 activation and the downregulation of its downstream MYC and E2F pathways by targeting UHRF1, resulting in the inhibition of leukemic potential of AML cells. The gene discussed is UHRF1; the disease is acute myeloid leukemia.